Transcript Building Dialogue Between Patients Organisations, Science

Building Dialogue Between
Patients Organisations,
Science and Industry
Eibhlin Mulroe MBA
Chief Executive
Information Day on HTAs
Where are we now?!
Eibhlin Mulroe MBA
Chief Executive
AGENDA: 5th April 2011
10.30 am
Registration & Coffee
11.00 am
Welcome & Introduction
Eibhlin Mulroe - CEO, IPPOSI
11.10 am
Outlining the HTA system in Ireland
and the current structure in place
Dr Mairin Ryan - HIQA
11.30 am
The academic perspective with a
particular focus on HTA’s and
Medical Devices
Prof Ciaran O’Neill – NUI Galway
Eibhlin Mulroe MBA
Chief Executive
AGENDA: 5th April 2011
11.50 am
The industry perspective in the
context of access and new
pharmaceuticals
Ms Jenny Hughes - GSK
12.20 pm
Discussion
12.30 pm
LUNCH
Eibhlin Mulroe MBA
Chief Executive
AGENDA: 5th April 2011
1.00 pm
The patient’s perspective, a look at
Europe and patient involvement in
the HTA process
Ms Liuska Sanna - European
Patients’ Forum
1.20 pm
Outlining Enterprise Ireland’s role
in guiding companies through
the system in Ireland
Ms Orlagh Murphy
Enterprise Ireland
1.40 pm
Discussion
2.00 pm
Eibhlin Mulroe MBA
Chief Executive
ACCESS TO MEDICINES AND
NEW MEDICAL TECHNOLOGIES IN THE
ERA OF HEALTH TECHNOLOGY
ASSESSMENTS IN IRELAND
DUBLIN, 24 NOVEMBER 2008
Eibhlin Mulroe MBA
Chief Executive
ACCESS TO MEDICINES AND
NEW MEDICAL TECHNOLOGIES IN THE
ERA OF HEALTH TECHNOLOGY
ASSESSMENTS IN IRELAND (2008)
•Ireland needs to foster a consensus based approach to the
development of HTAs/PEAs rather than a prescriptive
approach.
• The scope of HTA/PEA should not be limited to economic
considerations only. Social, ethical, legal considerations are
equally important.
• Patients and patient organisations need to be assisted
and
empowered to better understand HTA/PEA system and to
formally engage in the HTA/PEA process.
Eibhlin Mulroe MBA
Chief Executive
The position in 2008, have we moved on?
•Clarity is needed with regard to the role and purpose of
HTA/PEA in Ireland. The roles of NCPE and HIQA must be
clarified. Dialogue and consultation must be part of the
decision making process in establishing how HTA/PEA in
Ireland should move forward.
• Ireland must invest in terms of personnel and strategies
for
PEA/HTA; to target and entice appropriately qualified
people
into this expanding and increasingly important field of
expertise.
Eibhlin Mulroe MBA
Chief Executive
The position in 2008, have we moved on?
• HTA/PEA bodies must continue to ensure that clinical
experts
involved in Expert Advisory Groups for HTA/PEA have both
the
relevant specialisation AND the appropriate level of
expertise.
• Stakeholder participation, communication of HTA/PEA
results,
the sharing of HTA/PEA reports and opportunity for redress
are
essential and must be available for all HTAs/PEAs including
Mini PEA/HTAs1.
Eibhlin Mulroe MBA
Chief Executive
Further information
[email protected]
Eibhlin Mulroe MBA
Chief Executive